Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Promethazine

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section

Review note before using historical content

Promethazine historical concentration and infusion advice is superseded

The restored article already warns against IV push, but other concentration and infusion-time examples conflict with the later FDA labeling update. Deep intramuscular administration is preferred; if IV administration is necessary, follow the updated exact-product dilution and infusion instructions. Do not use the old maximum-IV-concentration sentence or infusion examples as current instructions.

Safety sources and review scope
  • FDA class-wide promethazine labeling safety update (opens in a new tab)Source URL: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-requires-updates-labeling-promethazine-hydrochloride-injection-products

    Exact location: 2023-12-27 notice: administration recommendation paragraph; If intramuscular injection is not possible bullets; adult and pediatric dilution/infusion tables

    Source family: FDA class-wide promethazine labeling safety update

    Scope: Official route/concentration/administration update; not a complete individual product monograph.

  • Promethazine U.S. prescribing information implementing FDA update (opens in a new tab)Source URL: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1d02d52b-84bb-4e81-b352-125029eb39f6

    Exact location: CONTRAINDICATIONS UUID0e9dd230-b07d-cda7-e063-6394a90ae084; DOSAGE AND ADMINISTRATION UUID0eade268-8023-e418-e063-6294a90a6ff9, Important Administration Information and Preparation/Administration for Diluted IV Infusion, Tables1/2

    Source family: Promethazine U.S. prescribing information implementing FDA update

    Scope: Example updated SPL version8 effective2024-01-05. It confirms the label change; stocked manufacturer/package and latest marketing status remain unreconciled.

Historical source in disagreement: Archived GlobalRPh article (opens in a new tab)Historical source URL: https://globalrph.com/dilution/promethazine/

Historical location: Drug Dilution:15–30 minute examples; Stability/Miscellaneous: Limit concentration paragraph and historical ISMP strategies

Review-note ID: H62-SAFETY-PROMETHAZINE-ADMINISTRATION. The historical source remains preserved; this note does not qualify its complete monograph.

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Promethazine (opens in a new tab)Original source URL: https://globalrph.com/dilution/promethazine/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/promethazine/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:47:24.201827+00:00
Source location
div.post-content
Packaged content SHA-256
2dd4f01d4b5b9cebbd4a0fc3532d9ab8b2a155ba12f47798a9daf216ea448069
Original response SHA-256
8356be5791a8cf5f99a89fc495f637c3dd450f1a5d5c268ed747f78741912194
Source body SHA-256
c675d139591292ad2d9f3b480197f6042ee80945fbf2ea8ee47cfdacaa9fec3f

Promethazine

The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents

NS, D5W

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]

Promethazine historical concentration and infusion advice is superseded

The restored article already warns against IV push, but other concentration and infusion-time examples conflict with the later FDA labeling update. Deep intramuscular administration is preferred; if IV administration is necessary, follow the updated exact-product dilution and infusion instructions. Do not use the old maximum-IV-concentration sentence or infusion examples as current instructions.

Current-source reference: 2023-12-27 notice: administration recommendation paragraph; If intramuscular injection is not possible bullets; adult and pediatric dilution/infusion tables

Current-source reference: CONTRAINDICATIONS UUID0e9dd230-b07d-cda7-e063-6394a90ae084; DOSAGE AND ADMINISTRATION UUID0eade268-8023-e418-e063-6294a90a6ff9, Important Administration Information and Preparation/Administration for Diluted IV Infusion, Tables1/2

Follow your local protocol....
Detroit VAMC Dilution:
[0 - 25 mg] [ 50 -100 ml] [ 15 - 30 min]

Concentration studied in Trissel: (0.1 mg/ml)
[12.5 mg] [ 125 ml] [ 15 to 30 min]
[25 mg] [ 250 ml] [ 15 to 30 min]

If a patient complains of pain during intended intravenous injection, stop the injection immediately; suspect inadvertent intra-arterial injection.

Stability / Miscellaneous

Promethazine historical concentration and infusion advice is superseded

The restored article already warns against IV push, but other concentration and infusion-time examples conflict with the later FDA labeling update. Deep intramuscular administration is preferred; if IV administration is necessary, follow the updated exact-product dilution and infusion instructions. Do not use the old maximum-IV-concentration sentence or infusion examples as current instructions.

Current-source reference: 2023-12-27 notice: administration recommendation paragraph; If intramuscular injection is not possible bullets; adult and pediatric dilution/infusion tables

Current-source reference: CONTRAINDICATIONS UUID0e9dd230-b07d-cda7-e063-6394a90ae084; DOSAGE AND ADMINISTRATION UUID0eade268-8023-e418-e063-6294a90a6ff9, Important Administration Information and Preparation/Administration for Diluted IV Infusion, Tables1/2

EXP: 1 DAY (RT)
Label: Do not Refrigerate. Protect from light.
If a patient complains of pain during intended intravenous injection, stop the injection immediately. DO NOT GIVE IV PUSH - MUST DILUTE FIRST AND ADMINISTER BY SLOW IV INFUSION- SEE BELOW. PREFERRED ROUTES: IM OR ORAL.

Subcutaneous or intra-arterial injection is contraindicated as these routes of administration may cause tissue necrosis and gangrene of the affected extremity, respectively (Prod Info Phenergan(R),).

Dilution opinion (D. McAuley):
A 10-fold dilution will result in a negligible change in the pH ( ~+ 0.3). NaCl is the salt of a strong acid and strong base and has a neutral pH. Promethazine is considered a weak acid and is only partially dissociated in solution. The degree of dissociation is proportional to its Ka (dissociation constant). Larger Ka --> stronger acid (greater dissociation). What does all this mean?? 1) The pH of promethazine after a 10-fold dilution (or greater) is still quite low. 2) The primary purpose of the dilution is to facilitate a slower administration rate and to reduce the amount of drug present per unit of volume.

Dosing (Adults): (Preferred routes: oral or IM). If administered IV, dilute drug and administer slowly as indicated above.
Allergic conditions (including allergic reactions to blood or plasma): Oral, rectal: 25 mg at bedtime or 12.5 mg before meals and at bedtime (range: 6.25 to 12.5 mg 3 times/day). I.M., I.V.: 25 mg, may repeat in 2 hours when necessary; switch to oral route as soon as feasible.

Antiemetic: Oral, I.M., I.V., rectal: 12.5 to 25 mg every 4 to 6 hours as needed.
Sedation: Oral, I.M., I.V., rectal: 12.5 to 50 mg/dose.

--------------------------------------------------------------------------------

Background information:

Title: Action needed to prevent serious tissue injury with IV promethazine.

"ISMP believes these long-standing hazards require further action on the part of healthcare providers, FDA, and promethazine manufacturers. In the 1970s, after numerous reports of infiltration and inadvertent intraarterial injection of hydroxyzine, FDA asked the manufacturer to revise the label and remove IV as an approved route. Today the drug is only indicated for IM or oral administration. Similarly, FDA should carefully investigate adverse events with this drug to determine if labeling changes are warranted, including removal of approval for IV administration."

Safe Practice Recommendations: ... [See ISMP for further info ] Limited direct quotes from this source.

Along with the manufacturer recommendations, the following strategies should be considered to prevent or minimize tissue damage when giving IV promethazine.... [See ISMP for further info ]

Limit concentration. Since 25 mg/mL is the highest concentration of promethazine that can be given IV, stock only this concentration (not the 50 mg/mL concentration). Limit the dose. Consider 6.25 to 12.5 mg of promethazine as the starting IV dose, especially for elderly patients. Hospitals have reported that these smaller doses have proven quite effective. Dilute the drug. Require further dilution of the 25 mg/mL strength to reduce vesicant effects and enable slow administration. For example, dilute the drug in 10 to 20 mL of normal saline if it will be administered via a running IV, or prepare the medication in minibags containing normal saline if there is time for pharmacy to dispense them as needed for individual patients. Extravasation can also be recognized more quickly when promethazine is diluted than if the drug is given in a smaller volume. Use large patent veins. Give the medication only through a large-bore vein (preferably via a central venous access site, but absolutely no hand or wrist veins). Check patency of the access site before administration... [See ISMP for further info ] Inject into the furthest port. Administer IV promethazine through a running IV line at the port furthest from the patient's vein. Educate patients. Before administration of the drug, tell patients to let you know immediately if burning or pain occurs during or after the injection. Use alternatives. Consider safer alternatives that can be used for the various conditions treated with IV promethazine. For example, 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists may be used for both prophylaxis and as a rescue antiemetic. ... [See ISMP for further info ] Remove from formulary. Some hospitals that have continued to experience adverse outcomes despite safety measures have removed promethazine from their formulary or banned its IV use.The above message comes from "ISMP", who is solely responsible for its content.

Nursing forum responses (Various sources - original sources unknown)
"At my hospital the doc's usually write for 6.25mg-12.5mg at a time. We give the full 25mg very rarely. I dilute it in 10cc NS and if fluids are running I hang it as a secondary over 10-20 minutes depending on the pt's vein status. I've pushed it diluted over 5 minutes before and it caused chemical phlebitis."

--------------------------------------------------------------------------------

"Mosby's drug guide for nurses states to dilute with 9ml NaCl and administer over 2 minutes. Always dilute phenergan when giving it IV. My DH was in ER a while ago for what turned out to be food poisoning, they gave him undiluted phenergan and his vein sclerosed from wrist to bicep (no I'm NOT exaggerating)"

--------------------------------------------------------------------------------

"As a nurse, I have had many patients complain aobut how much Phenergan burns. I would always just politely tell them them that it would burn and then push it slow diluted in 10 cc's of NS but then it was my turn. I was hospitalized and was given IV Phenergan and it not only burned like heck but I swear I felt like I was having a full blown MI. My entire arm was numb not to mention the IV site had to be changed and I developed phlebitis all around the site. I don't give Phenergan anymore without diluting it in 50 cc's of NS. I learned my lesson."

Open this historical article on its own

FDA safety resources for this medication (1)

Read the linked communication and current prescribing information before use. Resource dates and affected product scopes differ; a listed resource is not a full monograph or a lot-specific clearance.

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      promethazine
      Source IDH51-810DDF5B67158F7ED036FBAA
      Generic name
      Promethazine
      Source IDH51-7DB381B540D1C0CF7E5DDC18
      Class
      GI and antiemetic
      Source IDH51-5D3C1A80C2A601CDCEFAC265
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-668BC49E4171521ECD0628A9
      Primary uses
      1. Acid suppression, nausea and vomiting control, or gastrointestinal motility therapy, depending on the named agent.
        Source IDH51-5EBA6B8C15C7885D8052EA8B
      Mechanism
      Blocks histamine H1 receptors and also has antimuscarinic and antidopaminergic effects.
      Source IDH51-6446960CC82CE635941D055F
      Mechanism level
      drug_specific
      Source IDH51-3442D4737BC7BC65C636F3F7
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-7BA7E0C04517C459ED20B6F3
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-368C53A2D122590C52DACC1E
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-96F0262C3BA213AA926013F8
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-82105DE00B40B1C4971BAB8B
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-E90A3C9D04A477E45EC3C01E
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-ED97FE6366162DFC3E7189C9
      Legacy title
      Promethazine
      Source IDH51-C0FD181ABA32E3A090EE6A00
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-0C80C29C9209EDABD9C737C0
      Search text
      Promethazine GI and antiemetic Legacy GlobalRPh directory entry Acid suppression, nausea and vomiting control, or gastrointestinal motility therapy, depending on the named agent. Blocks histamine H1 receptors and also has antimuscarinic and antidopaminergic effects. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-E19BF844E12A080CEAE11CD3
      Official access mode
      none
      Source IDH51-761F81B5DDAA92A0098FB1B1
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-67C225361578BD98DAFAC6B0

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-328A510E466A5528FB8499DA
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-01879F875057619C61631CDA
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-CFBC4007F73C250058CB6B33

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-B13EFC8290F86BF3A4776BFC

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-2B52E4EDB4EC64766368E0FF
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      promethazine
      Source IDH51-2F56692F1191C1B5E8FE788E
      Legacy title
      Promethazine
      Source IDH51-9215BB74AB5FD401C21E51B8
      Generic name
      Promethazine
      Source IDH51-3CDF6F903495AFE79895313A
      Class
      GI and antiemetic
      Source IDH51-C70A68B97B657DDA017BA12A
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-F5DBEAEBBA5405925F5A7575
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-F837F497BEF5DE620C691B54
      Populations
      1. Population not yet normalized
        Source IDH51-1AFA90EF23997773F65748B7
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-85F7E3FE804FE9FF28438525
      High alert
      false
      Source IDH51-F087FEF73236BBD21B27AED3
      Hazardous
      false
      Source IDH51-E5DFC97055BF861E0059D803
      Status
      Legacy migration
      Source IDH51-F99DF1C09327E77BC5FDC2D3
      Version added
      Legacy
      Source IDH51-2785E74E6CFF335A2DFD6BC4
      Sources
      LabelUrlKind
      Source IDH51-DBB4C199D358F91C25EAD704
      GlobalRPh legacy IV dilution monograph
      Source IDH51-37554F3529DC15989D07EBC1
      legacy:auto
      Source IDH51-5027CA53FA326BFFC11A0815
      Legacy
      Source IDH51-8E7F400A3E2A50B721D89BB9
      Clinical release verification
      Audit version
      3.4
      Source IDH51-38B849E3A355D80649941038
      Audited on
      2026-08-30
      Source IDH51-785C5EFCF9142A7B4559E31C
      Level
      red
      Source IDH51-B67CB7CC5DE94FB3D0EA0DFE
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-CC5EA8E6942DF85F0290FF74
      Exact current label candidate
      false
      Source IDH51-1728472602389F49617E5F2E
      Reference url count
      0
      Source IDH51-BFC1474149C1D80903943761
      Broken reference count
      0
      Source IDH51-3B500BEB0F3E9AA0B53A39D3
      Point of use confirmation required
      true
      Source IDH51-93B9078B358EA834A44C337E
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-3B75874EC21F66818A691D5D

      Dosing source fields

      Id
      promethazine
      Source IDH51-40EDC2203BB2BA8128E1536A
      Generic name
      Promethazine
      Source IDH51-5D1C8EAD3B1D44C68A69F89C
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-5EBB38FB90F3E9B1B07CBAA1
      Package insert
      Query name
      Promethazine
      Source IDH51-A423BF40BF722B31A9049C5C
      Product and route must match
      true
      Source IDH51-FE8F7687AD8E894DAF5EED8E
      Live current label enabled
      false
      Source IDH51-10F4850FF61B948326EB9163
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-12DD83EC2EDDD299922C2D2D
      Direct official label access enabled
      true
      Source IDH51-D6402C192731310202E8DE6F
      Outbound server request required
      false
      Source IDH51-021D0DB33D500472A01AF185
      Local summary status
      not_bundled
      Source IDH51-D1000FF200CD325B46229EA5
      Clinical review
      Locally normalized
      false
      Source IDH51-6AD1C0B728E328A672F90794
      Reviewed
      2026-08-29
      Source IDH51-78FE8D3EF2142DAE2F968BD6
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-2FA576226C1400CD6AF2802B
      Clinical release verification
      Audit version
      3.4
      Source IDH51-2F37F9844D9F48C5115A6D5A
      Audited on
      2026-08-30
      Source IDH51-6A92DFD3F250A6556D0E5B61
      Level
      red
      Source IDH51-22CBB0B0CD0C7D1C195B8659
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-7F2741195BD7AB36274CF515
      Exact current label candidate
      false
      Source IDH51-087C4A5C459E9B4CBD34146E
      Reference url count
      0
      Source IDH51-41D8180A71BA0060DD045F6B
      Broken reference count
      0
      Source IDH51-B0A090F71AC795BEF7564F1A
      Point of use confirmation required
      true
      Source IDH51-060C405B3A1690D4529EBDB0
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-645E9494ECD600A76F439BA0
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      promethazine
      Source IDH51-157BA35A65DF37EEF194C665
      Name
      Promethazine
      Source IDH51-3277DFD72ED20CD73B483609
      Therapeutic class
      GI and antiemetic
      Source IDH51-7925ADE6FCA0CE78267CDD0D
      Review version
      3.1
      Source IDH51-3159DD2563E9F01EDED9414D
      Review date
      2026-08-30
      Source IDH51-924938BD41DDFD6C1B401AD3
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-E4BFC3E49988DDB6CE44D20F
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-7D270AA42F5E6029B7EA72C8
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-97117D3F7A990B3131AA3585
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-175B333F55C103320B06E6C4
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-40CC807AEB628042B41153F8
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-9E131B8EE17597D0F3545FB6
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-41AEA531AC7271691ADFC0A1
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-A3955D0FAF10AF27002E5E33
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-0E866F8AF0D3D77413C44EA3
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-714C0F65E041970523F88D3E
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-DF9704F08687F3E6F03E813E
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-7ADCC0F70A6B2E7CB1649120
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-D94B86B9EE01BC5FBB45098B
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-E3DC6035FF0A975FB63F4962
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-DEC81D90E4D4795C2F99937E
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-8B034038C0B3CC6B2D9A3A93
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-31B9D77F47A729CAD885EA5B
      Adult dosing range
      Primary
      not_found
      Source IDH51-F2AF8C2964039283D4A4D630
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-7912A2EAF8A93ED83FC64E0A
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-53D55403C00A8F2F5A987B0F
      Infusion time
      Primary
      not_found
      Source IDH51-37240E82186C80118C1FEEB6
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-DFA9E0445E47288690BC1156
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-E6F6C00791E703B5B90BBDCE
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-97CA7E077F04493D69C1A37F
      Guide generation allowed
      false
      Source IDH51-99CC1B3741CE666AE3897C2B
      Pediatric
      Applicability
      not_established
      Source IDH51-069899991D4078B7A099535A
      Guide generation allowed
      false
      Source IDH51-095AD054B622970CB1B655F9
      Neonatal
      Applicability
      not_established
      Source IDH51-A4272E745D8E701D4FB036F9
      Guide generation allowed
      false
      Source IDH51-7500756804D22799C4B5DCBC
      Route presence
      Structured dilution
      false
      Source IDH51-E480D233101C5B50561B13A8
      Iv push
      false
      Source IDH51-A4363F5F789E98F189EAAB7F
      Continuous infusion
      false
      Source IDH51-D2DD6CE54324F2D5E4FDB822
      Pediatric source
      false
      Source IDH51-EBB02ADECC938BF73F495ACB
      Neonatal source
      false
      Source IDH51-D3B99D89070FFA157ED90545
      Legacy reference
      Status
      not_available
      Source IDH51-B4664D400F522E00310CD7BC
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-9AE9446F28447BCDE9213902
      Source files
      1. catalog.json
        Source IDH51-56FB6F560A8516EEFB5A560B
      2. dosing.json
        Source IDH51-D03CEDD2D9CD62B7B078F886
      3. legacy-map.json
        Source IDH51-A28385F57DA1A9E4602EFD46
      4. review-queue.json
        Source IDH51-994E710DF0FD6554E70FA1D9
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-EABF9F008C51E1C179F0E746
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-2F56692F1191C1B5E8FE788Ecatalog.json
      /records/207/id
      Historical; current review incomplete
      H51-9215BB74AB5FD401C21E51B8catalog.json
      /records/207/legacy_title
      Historical; current review incomplete
      H51-3CDF6F903495AFE79895313Acatalog.json
      /records/207/generic_name
      Historical; current review incomplete
      H51-C70A68B97B657DDA017BA12Acatalog.json
      /records/207/class
      Historical; current review incomplete
      H51-F5DBEAEBBA5405925F5A7575catalog.json
      /records/207/subclass
      Historical; current review incomplete
      H51-F837F497BEF5DE620C691B54catalog.json
      /records/207/summary
      Historical; current review incomplete
      H51-B13EFC8290F86BF3A4776BFCcatalog.json
      /records/207/warnings/0
      Historical; current review incomplete
      H51-2B52E4EDB4EC64766368E0FFcatalog.json
      /records/207/stability_notes/0
      Historical; current review incomplete
      H51-1AFA90EF23997773F65748B7catalog.json
      /records/207/populations/0
      Historical; current review incomplete
      H51-85F7E3FE804FE9FF28438525catalog.json
      /records/207/evidence_tier
      Historical; current review incomplete
      H51-F087FEF73236BBD21B27AED3catalog.json
      /records/207/high_alert
      Historical; current review incomplete
      H51-E5DFC97055BF861E0059D803catalog.json
      /records/207/hazardous
      Historical; current review incomplete
      H51-F99DF1C09327E77BC5FDC2D3catalog.json
      /records/207/status
      Historical; current review incomplete
      H51-3E3BE2F8D19A8BF9519CBD41catalog.json
      /records/207/reviewed
      Historical; current review incomplete
      H51-2785E74E6CFF335A2DFD6BC4catalog.json
      /records/207/version_added
      Historical; current review incomplete
      H51-DBB4C199D358F91C25EAD704catalog.json
      /records/207/sources/0
      Historical; current review incomplete
      H51-37554F3529DC15989D07EBC1catalog.json
      /records/207/sources/0/label
      Historical; current review incomplete
      H51-5027CA53FA326BFFC11A0815catalog.json
      /records/207/sources/0/url
      Historical; current review incomplete
      H51-8E7F400A3E2A50B721D89BB9catalog.json
      /records/207/sources/0/kind
      Historical; current review incomplete
      H51-38B849E3A355D80649941038catalog.json
      /records/207/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-785C5EFCF9142A7B4559E31Ccatalog.json
      /records/207/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-B67CB7CC5DE94FB3D0EA0DFEcatalog.json
      /records/207/clinical_release_verification/level
      Historical; current review incomplete
      H51-CC5EA8E6942DF85F0290FF74catalog.json
      /records/207/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-1728472602389F49617E5F2Ecatalog.json
      /records/207/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-62F16532A5FEAA75E472C9C6catalog.json
      /records/207/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-BE4BA23EF771B4C9F89CA69Fcatalog.json
      /records/207/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-80F22772F7A429F6DD7DA408catalog.json
      /records/207/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-BFC1474149C1D80903943761catalog.json
      /records/207/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-3B500BEB0F3E9AA0B53A39D3catalog.json
      /records/207/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-93B9078B358EA834A44C337Ecatalog.json
      /records/207/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-3B75874EC21F66818A691D5Dcatalog.json
      /records/207/clinical_release_verification/note
      Historical; current review incomplete
      H51-AB7AC9923883098E60146D11catalog.json
      /records/207/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-40EDC2203BB2BA8128E1536Adosing.json
      /records/207/id
      Historical; current review incomplete
      H51-5D1C8EAD3B1D44C68A69F89Cdosing.json
      /records/207/generic_name
      Historical; current review incomplete
      H51-5EBB38FB90F3E9B1B07CBAA1dosing.json
      /records/207/coverage_status
      Historical; current review incomplete
      H51-A423BF40BF722B31A9049C5Cdosing.json
      /records/207/package_insert/query_name
      Historical; current review incomplete
      H51-A39A13A2D4CDDEFB4DC42557dosing.json
      /records/207/package_insert/preferred_setid
      Historical; current review incomplete
      H51-FE8F7687AD8E894DAF5EED8Edosing.json
      /records/207/package_insert/product_and_route_must_match
      Historical; current review incomplete
      H51-10F4850FF61B948326EB9163dosing.json
      /records/207/package_insert/live_current_label_enabled
      Historical; current review incomplete
      H51-12DD83EC2EDDD299922C2D2Ddosing.json
      /records/207/package_insert/source_priority
      Historical; current review incomplete
      H51-D6402C192731310202E8DE6Fdosing.json
      /records/207/package_insert/direct_official_label_access_enabled
      Historical; current review incomplete
      H51-021D0DB33D500472A01AF185dosing.json
      /records/207/package_insert/outbound_server_request_required
      Historical; current review incomplete
      H51-D1000FF200CD325B46229EA5dosing.json
      /records/207/package_insert/local_summary_status
      Historical; current review incomplete
      H51-328A510E466A5528FB8499DAdosing.json
      /records/207/renal/classification
      Historical; current review incomplete
      H51-01879F875057619C61631CDAdosing.json
      /records/207/renal/summary
      Historical; current review incomplete
      H51-CFBC4007F73C250058CB6B33dosing.json
      /records/207/renal/method_note
      Historical; current review incomplete
      H51-6AD1C0B728E328A672F90794dosing.json
      /records/207/clinical_review/locally_normalized
      Historical; current review incomplete
      H51-78FE8D3EF2142DAE2F968BD6dosing.json
      /records/207/clinical_review/reviewed
      Historical; current review incomplete
      H51-2FA576226C1400CD6AF2802Bdosing.json
      /records/207/clinical_review/status
      Historical; current review incomplete
      H51-2F37F9844D9F48C5115A6D5Adosing.json
      /records/207/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-6A92DFD3F250A6556D0E5B61dosing.json
      /records/207/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-22CBB0B0CD0C7D1C195B8659dosing.json
      /records/207/clinical_release_verification/level
      Historical; current review incomplete
      H51-7F2741195BD7AB36274CF515dosing.json
      /records/207/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-087C4A5C459E9B4CBD34146Edosing.json
      /records/207/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-D1649854A54ADE72294AE0B9dosing.json
      /records/207/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-40E511981E60167C8E204335dosing.json
      /records/207/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-C303351CE80B4A571B2C58F1dosing.json
      /records/207/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-41D8180A71BA0060DD045F6Bdosing.json
      /records/207/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-B0A090F71AC795BEF7564F1Adosing.json
      /records/207/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-060C405B3A1690D4529EBDB0dosing.json
      /records/207/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-645E9494ECD600A76F439BA0dosing.json
      /records/207/clinical_release_verification/note
      Historical; current review incomplete
      H51-EFC60139CB4619FF19DB4A0Adosing.json
      /records/207/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-810DDF5B67158F7ED036FBAAfirst-look-v5.1.json
      /records/207/id
      Historical; current review incomplete
      H51-7DB381B540D1C0CF7E5DDC18first-look-v5.1.json
      /records/207/generic_name
      Historical; current review incomplete
      H51-5D3C1A80C2A601CDCEFAC265first-look-v5.1.json
      /records/207/class
      Historical; current review incomplete
      H51-668BC49E4171521ECD0628A9first-look-v5.1.json
      /records/207/subclass
      Historical; current review incomplete
      H51-5EBA6B8C15C7885D8052EA8Bfirst-look-v5.1.json
      /records/207/primary_uses/0
      Historical; current review incomplete
      H51-6446960CC82CE635941D055Ffirst-look-v5.1.json
      /records/207/mechanism
      Historical; current review incomplete
      H51-3442D4737BC7BC65C636F3F7first-look-v5.1.json
      /records/207/mechanism_level
      Historical; current review incomplete
      H51-7BA7E0C04517C459ED20B6F3first-look-v5.1.json
      /records/207/basic_dosing_orientation
      Historical; current review incomplete
      H51-368C53A2D122590C52DACC1Efirst-look-v5.1.json
      /records/207/administration_orientation
      Historical; current review incomplete
      H51-96F0262C3BA213AA926013F8first-look-v5.1.json
      /records/207/renal_and_population_orientation
      Historical; current review incomplete
      H51-82105DE00B40B1C4971BAB8Bfirst-look-v5.1.json
      /records/207/key_safety_orientation/0
      Historical; current review incomplete
      H51-E90A3C9D04A477E45EC3C01Efirst-look-v5.1.json
      /records/207/coverage_path
      Historical; current review incomplete
      H51-ED97FE6366162DFC3E7189C9first-look-v5.1.json
      /records/207/coverage_path_label
      Historical; current review incomplete
      H51-CCDD0B572E36D049C5C49E2Afirst-look-v5.1.json
      /records/207/official_label_url
      Historical; current review incomplete
      H51-C0FD181ABA32E3A090EE6A00first-look-v5.1.json
      /records/207/legacy_title
      Historical; current review incomplete
      H51-0C80C29C9209EDABD9C737C0first-look-v5.1.json
      /records/207/review_note
      Historical; current review incomplete
      H51-E19BF844E12A080CEAE11CD3first-look-v5.1.json
      /records/207/search_text
      Historical; current review incomplete
      H51-1751CA30B067194255927B2Ffirst-look-v5.1.json
      /records/207/official_search_url
      Historical; current review incomplete
      H51-761F81B5DDAA92A0098FB1B1first-look-v5.1.json
      /records/207/official_access_mode
      Historical; current review incomplete
      H51-019AC30990D44D109F4C3383first-look-v5.1.json
      /records/207/official_access_url
      Historical; current review incomplete
      H51-8500A1BADFF233B8A42887B9first-look-v5.1.json
      /records/207/official_search_query
      Historical; current review incomplete
      H51-67C225361578BD98DAFAC6B0first-look-v5.1.json
      /records/207/official_access_reason
      Historical; current review incomplete
      H51-157BA35A65DF37EEF194C665preparation-assessments-v3.8.json
      /207/id
      Historical; current review incomplete
      H51-3277DFD72ED20CD73B483609preparation-assessments-v3.8.json
      /207/name
      Historical; current review incomplete
      H51-60D4BE364D8F65DB2025C8DDpreparation-assessments-v3.8.json
      /207/brands
      Historical; current review incomplete
      H51-7925ADE6FCA0CE78267CDD0Dpreparation-assessments-v3.8.json
      /207/therapeutic_class
      Historical; current review incomplete
      H51-3159DD2563E9F01EDED9414Dpreparation-assessments-v3.8.json
      /207/review_version
      Historical; current review incomplete
      H51-924938BD41DDFD6C1B401AD3preparation-assessments-v3.8.json
      /207/review_date
      Historical; current review incomplete
      H51-E4BFC3E49988DDB6CE44D20Fpreparation-assessments-v3.8.json
      /207/release_status
      Historical; current review incomplete
      H51-7D270AA42F5E6029B7EA72C8preparation-assessments-v3.8.json
      /207/market_status/status
      Historical; current review incomplete
      H51-97117D3F7A990B3131AA3585preparation-assessments-v3.8.json
      /207/market_status/basis
      Historical; current review incomplete
      H51-175B333F55C103320B06E6C4preparation-assessments-v3.8.json
      /207/ten_point_assessment/exact_formulation
      Historical; current review incomplete
      H51-40CC807AEB628042B41153F8preparation-assessments-v3.8.json
      /207/ten_point_assessment/reconstitution_concentration
      Historical; current review incomplete
      H51-9E131B8EE17597D0F3545FB6preparation-assessments-v3.8.json
      /207/ten_point_assessment/maximum_or_recommended_final_concentration
      Historical; current review incomplete
      H51-41AEA531AC7271691ADFC0A1preparation-assessments-v3.8.json
      /207/ten_point_assessment/appropriate_standardized_containers
      Historical; current review incomplete
      H51-A3955D0FAF10AF27002E5E33preparation-assessments-v3.8.json
      /207/ten_point_assessment/adult_dosing_range
      Historical; current review incomplete
      H51-0E866F8AF0D3D77413C44EA3preparation-assessments-v3.8.json
      /207/ten_point_assessment/pediatric_dosing_range
      Historical; current review incomplete
      H51-714C0F65E041970523F88D3Epreparation-assessments-v3.8.json
      /207/ten_point_assessment/neonatal_dosing_range
      Historical; current review incomplete
      H51-DF9704F08687F3E6F03E813Epreparation-assessments-v3.8.json
      /207/ten_point_assessment/infusion_time
      Historical; current review incomplete
      H51-7ADCC0F70A6B2E7CB1649120preparation-assessments-v3.8.json
      /207/ten_point_assessment/fluid_restriction_alternatives
      Historical; current review incomplete
      H51-98C9641E42816E24D0CCA780preparation-assessments-v3.8.json
      /207/ten_point_assessment/current_manufacturer_labeling/setid
      Historical; current review incomplete
      H51-79DEF39279FC1B091DB093C2preparation-assessments-v3.8.json
      /207/ten_point_assessment/current_manufacturer_labeling/title
      Historical; current review incomplete
      H51-2C8CC8C9ACFF300236F027CFpreparation-assessments-v3.8.json
      /207/ten_point_assessment/current_manufacturer_labeling/published_date
      Historical; current review incomplete
      H51-62ABCC5689F0F55FEBF276AFpreparation-assessments-v3.8.json
      /207/ten_point_assessment/current_manufacturer_labeling/manufacturer
      Historical; current review incomplete
      H51-D94B86B9EE01BC5FBB45098Bpreparation-assessments-v3.8.json
      /207/ten_point_assessment/current_manufacturer_labeling/match_confidence
      Historical; current review incomplete
      H51-65BA2147BE3EE7721260CA31preparation-assessments-v3.8.json
      /207/ten_point_assessment/current_manufacturer_labeling/url
      Historical; current review incomplete
      H51-E3DC6035FF0A975FB63F4962preparation-assessments-v3.8.json
      /207/field_provenance/exact_formulation/primary
      Historical; current review incomplete
      H51-DEC81D90E4D4795C2F99937Epreparation-assessments-v3.8.json
      /207/field_provenance/reconstitution_concentration/primary
      Historical; current review incomplete
      H51-8B034038C0B3CC6B2D9A3A93preparation-assessments-v3.8.json
      /207/field_provenance/maximum_or_recommended_final_concentration/primary
      Historical; current review incomplete
      H51-31B9D77F47A729CAD885EA5Bpreparation-assessments-v3.8.json
      /207/field_provenance/appropriate_standardized_containers/primary
      Historical; current review incomplete
      H51-F2AF8C2964039283D4A4D630preparation-assessments-v3.8.json
      /207/field_provenance/adult_dosing_range/primary
      Historical; current review incomplete
      H51-7912A2EAF8A93ED83FC64E0Apreparation-assessments-v3.8.json
      /207/field_provenance/pediatric_dosing_range/primary
      Historical; current review incomplete
      H51-53D55403C00A8F2F5A987B0Fpreparation-assessments-v3.8.json
      /207/field_provenance/neonatal_dosing_range/primary
      Historical; current review incomplete
      H51-37240E82186C80118C1FEEB6preparation-assessments-v3.8.json
      /207/field_provenance/infusion_time/primary
      Historical; current review incomplete
      H51-DFA9E0445E47288690BC1156preparation-assessments-v3.8.json
      /207/field_provenance/fluid_restriction_alternatives/primary
      Historical; current review incomplete
      H51-E6F6C00791E703B5B90BBDCEpreparation-assessments-v3.8.json
      /207/field_provenance/current_manufacturer_labeling/primary
      Historical; current review incomplete
      H51-97CA7E077F04493D69C1A37Fpreparation-assessments-v3.8.json
      /207/population_applicability/adult/applicability
      Historical; current review incomplete
      H51-99CC1B3741CE666AE3897C2Bpreparation-assessments-v3.8.json
      /207/population_applicability/adult/guide_generation_allowed
      Historical; current review incomplete
      H51-069899991D4078B7A099535Apreparation-assessments-v3.8.json
      /207/population_applicability/pediatric/applicability
      Historical; current review incomplete
      H51-095AD054B622970CB1B655F9preparation-assessments-v3.8.json
      /207/population_applicability/pediatric/guide_generation_allowed
      Historical; current review incomplete
      H51-A4272E745D8E701D4FB036F9preparation-assessments-v3.8.json
      /207/population_applicability/neonatal/applicability
      Historical; current review incomplete
      H51-7500756804D22799C4B5DCBCpreparation-assessments-v3.8.json
      /207/population_applicability/neonatal/guide_generation_allowed
      Historical; current review incomplete
      H51-E480D233101C5B50561B13A8preparation-assessments-v3.8.json
      /207/route_presence/structured_dilution
      Historical; current review incomplete
      H51-A4363F5F789E98F189EAAB7Fpreparation-assessments-v3.8.json
      /207/route_presence/iv_push
      Historical; current review incomplete
      H51-D2DD6CE54324F2D5E4FDB822preparation-assessments-v3.8.json
      /207/route_presence/continuous_infusion
      Historical; current review incomplete
      H51-EBB02ADECC938BF73F495ACBpreparation-assessments-v3.8.json
      /207/route_presence/pediatric_source
      Historical; current review incomplete
      H51-D3B99D89070FFA157ED90545preparation-assessments-v3.8.json
      /207/route_presence/neonatal_source
      Historical; current review incomplete
      H51-B4664D400F522E00310CD7BCpreparation-assessments-v3.8.json
      /207/legacy_reference/status
      Historical; current review incomplete
      H51-9AE9446F28447BCDE9213902preparation-assessments-v3.8.json
      /207/label_resolution/status
      Historical; current review incomplete
      H51-56FB6F560A8516EEFB5A560Bpreparation-assessments-v3.8.json
      /207/source_files/0
      Historical; current review incomplete
      H51-D03CEDD2D9CD62B7B078F886preparation-assessments-v3.8.json
      /207/source_files/1
      Historical; current review incomplete
      H51-A28385F57DA1A9E4602EFD46preparation-assessments-v3.8.json
      /207/source_files/2
      Historical; current review incomplete
      H51-994E710DF0FD6554E70FA1D9preparation-assessments-v3.8.json
      /207/source_files/3
      Historical; current review incomplete
      H51-EABF9F008C51E1C179F0E746preparation-assessments-v3.8.json
      /207/clinical_release_note
      Historical; current review incomplete